DK1076566T3 - Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet - Google Patents
Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenetInfo
- Publication number
- DK1076566T3 DK1076566T3 DK99919755T DK99919755T DK1076566T3 DK 1076566 T3 DK1076566 T3 DK 1076566T3 DK 99919755 T DK99919755 T DK 99919755T DK 99919755 T DK99919755 T DK 99919755T DK 1076566 T3 DK1076566 T3 DK 1076566T3
- Authority
- DK
- Denmark
- Prior art keywords
- antigen
- express
- constructively
- attenuated salmonella
- salmonella mutants
- Prior art date
Links
- 241000607142 Salmonella Species 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 230000002238 attenuated effect Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 208000037386 Typhoid Diseases 0.000 abstract 1
- 229940023832 live vector-vaccine Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000008297 typhoid fever Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/879—Salmonella
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/076,761 US6190669B1 (en) | 1998-05-13 | 1998-05-13 | Attenuated mutants of salmonella which constitutively express the Vi antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1076566T3 true DK1076566T3 (da) | 2006-11-13 |
Family
ID=22134022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99919755T DK1076566T3 (da) | 1998-05-13 | 1999-04-30 | Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet |
Country Status (16)
Country | Link |
---|---|
US (1) | US6190669B1 (da) |
EP (1) | EP1076566B1 (da) |
JP (1) | JP4363782B2 (da) |
AT (1) | ATE333285T1 (da) |
AU (1) | AU754795B2 (da) |
CA (1) | CA2328056C (da) |
DE (1) | DE69932425T2 (da) |
DK (1) | DK1076566T3 (da) |
ES (1) | ES2268864T3 (da) |
HU (1) | HUP0101747A3 (da) |
MX (1) | MXPA00011075A (da) |
NO (1) | NO20005672L (da) |
NZ (1) | NZ508110A (da) |
PL (1) | PL192378B1 (da) |
WO (1) | WO1999058146A1 (da) |
ZA (1) | ZA200006381B (da) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69322645T2 (de) * | 1992-07-31 | 1999-05-20 | Medeva Holdings B.V., Amsterdam | Expression rekombinanter fusionsproteine in attenuierten bakterien |
GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
US6797275B1 (en) * | 1998-12-04 | 2004-09-28 | The United States Of America As Represented By The Department Of Health And Human Services | Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine |
DE69930147T2 (de) * | 1998-12-04 | 2007-01-11 | University Of Manitoba, Winnipeg | Zwei-schritte-verfahren zur impfung gegen chlamydia |
US7026155B2 (en) * | 1999-02-02 | 2006-04-11 | Regents Of The University Of California | Method of reducing bacterial proliferation |
EP1112747B1 (en) * | 1999-12-28 | 2004-06-16 | Akzo Nobel N.V. | Salmonella vaccine not inducing antibodies against flagellin or flagella |
US6902736B2 (en) * | 2000-04-20 | 2005-06-07 | University Of Maryland, Baltimore | Isolation and characterization of the csa operon (ETEC-CS4 pili) and methods of using same |
US7780961B2 (en) * | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
DE60319822T2 (de) * | 2002-06-19 | 2009-06-04 | Actogenix Nv | Verfahren und mittel zur erhöhung der darmabsorption |
WO2004046346A2 (en) * | 2002-11-15 | 2004-06-03 | Vib Vzw | Self-containing lactobacillus strain |
JP2009516503A (ja) * | 2005-10-28 | 2009-04-23 | ユニバーシティ オブ メリーランド, ボルチモア | 弱毒化s・パラチフスa菌株およびその使用 |
US8137930B2 (en) | 2005-10-28 | 2012-03-20 | University Of Maryland, Baltimore | Attenuated Salmonella enterica serovar paratyphi A and uses thereof |
WO2007062371A2 (en) * | 2005-11-23 | 2007-05-31 | University Of Maryland, Baltimore | Live vector vaccine and uses thereof |
EP2119450B1 (en) | 2005-11-29 | 2013-02-13 | Actogenix N.V. | Induction of mucosal tolerance to pancreatic islet beta-cell autoantigens |
WO2007112518A1 (en) * | 2006-03-20 | 2007-10-11 | Vrije Universiteit Brussel | Live attenuated salmonella vaccine |
CA2646421A1 (en) * | 2006-03-20 | 2007-10-11 | Vrije Universiteit Brussel | Live attenuated salmonella vaccine |
EP2066339B1 (en) * | 2006-09-18 | 2014-08-13 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses |
ES2492468T3 (es) | 2007-01-25 | 2014-09-09 | Actogenix N.V. | Tratamiento de enfermedad inmunitaria por administración a través de la mucosa de antígenos usando Lactobacillus genéticamente modificado |
US20110020399A1 (en) * | 2007-04-16 | 2011-01-27 | University Of Maryland, Baltimore | Vaccines and Immunomodulatory Therapies for Tularemia |
NZ585776A (en) * | 2007-10-30 | 2012-07-27 | Univ Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
WO2009059298A2 (en) | 2007-11-01 | 2009-05-07 | Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancinc immune responses to eimeria |
WO2010036226A1 (en) * | 2008-09-26 | 2010-04-01 | George Nelson | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
WO2010141143A2 (en) * | 2009-04-21 | 2010-12-09 | Vivocure, Inc. | Engineered avirulent bacteria strains and use in medical treatments |
CN102811734B (zh) | 2010-01-21 | 2016-02-10 | 阿肯色大学评议会 | 增强免疫应答的疫苗载体和方法 |
ES2753142T3 (es) | 2010-06-09 | 2020-04-07 | Univ Arkansas | Vacuna y métodos para reducir una infección por Campylobacter |
US9833503B2 (en) | 2012-02-24 | 2017-12-05 | President And Fellows Of Harvard College | Methods for displaying polypeptides and uses thereof |
ES2968398T3 (es) | 2013-02-14 | 2024-05-09 | Univ Arkansas | Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria |
EP3578190A1 (en) | 2013-03-15 | 2019-12-11 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
TWI843057B (zh) | 2016-05-03 | 2024-05-21 | 阿肯色州大學董事會 | 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法 |
US20250000913A1 (en) * | 2021-09-10 | 2025-01-02 | Regents Of The University Of Minnesota | Salmonella engineered for nontoxic colonization of tumors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
US5783196A (en) | 1996-04-09 | 1998-07-21 | University Of Maryland At Baltimore | Gua mutants of shigella spp. and vaccines containing the same |
-
1998
- 1998-05-13 US US09/076,761 patent/US6190669B1/en not_active Expired - Lifetime
-
1999
- 1999-04-30 AU AU37405/99A patent/AU754795B2/en not_active Expired
- 1999-04-30 PL PL344593A patent/PL192378B1/pl unknown
- 1999-04-30 WO PCT/US1999/006554 patent/WO1999058146A1/en active IP Right Grant
- 1999-04-30 HU HU0101747A patent/HUP0101747A3/hu unknown
- 1999-04-30 DK DK99919755T patent/DK1076566T3/da active
- 1999-04-30 JP JP2000547997A patent/JP4363782B2/ja not_active Expired - Fee Related
- 1999-04-30 AT AT99919755T patent/ATE333285T1/de not_active IP Right Cessation
- 1999-04-30 DE DE69932425T patent/DE69932425T2/de not_active Expired - Lifetime
- 1999-04-30 EP EP99919755A patent/EP1076566B1/en not_active Expired - Lifetime
- 1999-04-30 ES ES99919755T patent/ES2268864T3/es not_active Expired - Lifetime
- 1999-04-30 MX MXPA00011075A patent/MXPA00011075A/es not_active IP Right Cessation
- 1999-04-30 NZ NZ508110A patent/NZ508110A/xx unknown
- 1999-04-30 CA CA2328056A patent/CA2328056C/en not_active Expired - Lifetime
-
2000
- 2000-11-07 ZA ZA200006381A patent/ZA200006381B/en unknown
- 2000-11-10 NO NO20005672A patent/NO20005672L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU754795B2 (en) | 2002-11-28 |
NO20005672L (no) | 2001-01-15 |
PL344593A1 (en) | 2001-11-05 |
NO20005672D0 (no) | 2000-11-10 |
CA2328056C (en) | 2010-07-06 |
WO1999058146A1 (en) | 1999-11-18 |
ES2268864T3 (es) | 2007-03-16 |
JP4363782B2 (ja) | 2009-11-11 |
PL192378B1 (pl) | 2006-10-31 |
HUP0101747A3 (en) | 2002-03-28 |
EP1076566A1 (en) | 2001-02-21 |
DE69932425D1 (de) | 2006-08-31 |
DE69932425T2 (de) | 2007-03-08 |
ZA200006381B (en) | 2002-02-07 |
NZ508110A (en) | 2002-10-25 |
MXPA00011075A (es) | 2002-04-24 |
US6190669B1 (en) | 2001-02-20 |
EP1076566B1 (en) | 2006-07-19 |
JP2002514398A (ja) | 2002-05-21 |
EP1076566A4 (en) | 2005-01-05 |
CA2328056A1 (en) | 1999-11-18 |
ATE333285T1 (de) | 2006-08-15 |
HUP0101747A2 (hu) | 2001-09-28 |
AU3740599A (en) | 1999-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1076566T3 (da) | Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet | |
EP1032417A4 (en) | BACTERIAL VACCINES CONTAINING ATTENUATED AUXOTROPHIC STRAINS OF LISTERIA EXPRESSING HETEROLOGIC ANTIGENS | |
DK142391D0 (da) | Indretning til tilberedning, servering og opbevaring af f.eks. madvarer | |
EA200100773A1 (ru) | Замещенные 1-гетероциклические диариламины | |
DK1113816T3 (da) | Influenzavirus-vaccinesammensætning | |
RU92004496A (ru) | Новые пиперазинил- и пиперидинилциклогексанолы | |
EA200300464A1 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ | |
BR9916132A (pt) | Composições e utilização das mesmas | |
FI913215A0 (fi) | Additionspolymeriseringskatalysator, som aktiveras medelst oxidering. | |
DK1362597T3 (da) | Antigene peptider, der er afledt af telomerase | |
GEP20105118B (en) | Anti-vegf antibodies | |
TR199600128A2 (tr) | Sekil verilebilir, isiya karsi stabilize edilebilir dokunmus bukleli mamuller. | |
DK1545597T3 (da) | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons | |
MX9102850A (es) | Composiciones polimericas que contienen halogeno, estabilizadas. | |
NO910739L (no) | Sementeringsmateriale for olje, gass- og vannbroenner. | |
DE69738512D1 (de) | Epstein-barr virus type b ctl epitopen | |
DE69102205D1 (de) | Oberflächenaktive Polyorganosiloxane. | |
ES1017793Y (es) | Aparato refrigerador, especialmente frigorifico domestico. | |
FI912056A0 (fi) | Kopplingsanordning, vilken omfattar efter varandra foeljande kopplingssektioner. | |
EA199800753A1 (ru) | Бензотиофены, составы их содержащие и способы с их использованием | |
NO990849D0 (no) | Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner | |
IT8123022A0 (it) | Frigorifero, congelatore o simile, elettrodomestico, in particolare perfezionato. | |
AU3487799A (en) | Improved live attenuated viruses for use as vectors or vaccines | |
IT8223644A0 (it) | Serracavo, particolarmente per elettrodomestici o simili. | |
IT9019153A1 (it) | Valvola cardiaca artificiale, con elevatissimo grado di sicurezza |